Jun. 29, 2010 (Filing Services Canada) -- BioWest Therapeutics Inc. (BWE - TSX), ("Biowest" or the "Company"), announced today that Jeff Charpentier was appointed chief financial officer of the Company effective June 28, 2010. Prior to joining BioWest, Mr. Charpentier held a series of progressively senior roles at several public companies in the pharmaceutical and technology sectors. Over the course of the past fifteen years, Mr. Charpentier has successively served as chief financial officer of each of Inex Pharmaceuticals Corporation, Chromos Molecular Systems Inc. and Lignol Energy Corporation. Mr. Charpentier is experienced with public issuer reporting requirements in both Canada and the U.S. and has extensive experience in high-growth technology sectors. Mr. Charpentier has a Bachelor of Commerce from the University of British Columbia and is a Chartered Accountant (BC).
Bruce Schmidt resigned from his position as interim chief financial officer and president of the Company effective June 28, 2010, but will continue in his role as corporate secretary and as a director of Biowest.
Contact: Paul Brennan
Tel: (604) 790-4671
BioWest is committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs for the treatment of unmeet medical needs for various diseases. The Company's programs include drug candidates for: the prevention of catheter related infections, for the treatment of hospital-acquired infections, the treatment of dermatological diseases, and the treatment of hepatitis B infections. BioWest is headquartered in Vancouver, British Columbia, Canada.
Source: BioWest Therapeutics Inc. (TSX - BWE) http://www.migenix.com
Maximum News Dissemination by Filing Services Canada Inc. *